Drug Profile

RO 7795081

Alternative Names: CT-996; RG-6652; RO-7795081

Latest Information Update: 08 Sep 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Carmot Therapeutics
Developer Carmot Therapeutics; Roche
Class Antihyperglycaemics; Obesity therapies; Small molecules
Mechanism of Action Glucagon-like peptide-1 receptor agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase II Obesity; Type 2 diabetes mellitus

Most Recent Events

31 Aug 2026 Roche initiates a phase I pharmacokinetics trial in Healthy volunteers in USA (PO) (NCT07741604)
03 Aug 2026 Hoffmann-La Roche plans a phase I trial for Renal impairment (In Volunteers) (PO) in August 2026 (NCT07741604)
22 Jul 2026 Roche completes a phase-II trial in Obesity in USA (PO) (NCT07081958)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com